What is the dosage and treatment duration of Azithromycin for various bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Azithromycin Dosing and Treatment Duration

Azithromycin dosing varies significantly by indication, with the most common adult regimen being 500 mg on day 1 followed by 250 mg daily for days 2-5 (total 1.5 g), though sexually transmitted infections require a single 1 gram dose for optimal compliance. 1

Standard Adult Dosing by Indication

Respiratory Tract Infections

  • Community-acquired pneumonia (mild): 500 mg on day 1, then 250 mg once daily on days 2-5 1
  • Acute bacterial exacerbations of COPD: Either 500 mg daily for 3 days OR 500 mg on day 1, then 250 mg daily on days 2-5 1
  • Acute bacterial sinusitis: 500 mg daily for 3 days 1
  • Pharyngitis/tonsillitis (second-line): 500 mg on day 1, then 250 mg daily on days 2-5 1

Important caveat: Azithromycin is not first-line for streptococcal pharyngitis due to variable macrolide resistance and should only be used in penicillin-allergic patients 2

Sexually Transmitted Infections

  • Non-gonococcal urethritis/cervicitis (Chlamydia): Single 1 gram dose 1, 3
  • Gonococcal urethritis/cervicitis: Single 2 gram dose 1
  • Chancroid (genital ulcer disease): Single 1 gram dose 1

The single-dose regimen is critical for compliance and allows directly observed therapy, particularly important in populations unlikely to return for follow-up 3. Patients must abstain from sexual intercourse for 7 days after completing therapy 3.

Skin and Soft Tissue Infections

  • Uncomplicated infections: 500 mg on day 1, then 250 mg daily on days 2-5, with total duration approximately 7 days depending on clinical response 1, 4

Special Respiratory Conditions

  • Legionnaires' disease (hospitalized): 500 mg IV daily for 2-7 days, then oral to complete 7-10 days total 2
  • Legionnaires' disease (non-hospitalized): 500 mg on day 1, then 250 mg daily for 4 additional days 2

Long-Term Prophylactic Regimens

  • Bronchiectasis with ≥3 exacerbations/year: 500 mg three times weekly for minimum 6-12 months 3, 5
    • Alternative: 250 mg daily 3
  • Bronchiolitis obliterans syndrome (lung transplant): 250 mg daily for 5 days, then 250 mg three times weekly for at least 3 months 3
  • MAC prophylaxis in AIDS (CD4 <50): 1,200 mg once weekly 3
  • Disseminated MAC disease in AIDS: 250 mg daily with ethambutol, with or without rifabutin 3

Pediatric Dosing by Indication

Respiratory Tract Infections

  • Acute otitis media: Three options 1:
    • Single 30 mg/kg dose (1-day regimen)
    • 10 mg/kg once daily for 3 days (3-day regimen)
    • 10 mg/kg on day 1, then 5 mg/kg daily on days 2-5 (5-day regimen)
  • Acute bacterial sinusitis: 10 mg/kg once daily for 3 days 1
  • Community-acquired pneumonia: 10 mg/kg on day 1, then 5 mg/kg daily on days 2-5 1
  • Pharyngitis/tonsillitis: 12 mg/kg once daily for 5 days (ages ≥2 years) 1

The higher 12 mg/kg dose for pharyngitis is necessary to prevent recurrence, which occurs more frequently with standard dosing compared to penicillin 6.

Atypical Pathogens (Mycoplasma, Chlamydia pneumoniae)

  • 10 mg/kg on days 1-2, then transition to oral OR 10 mg/kg on day 1, then 5 mg/kg daily on days 2-5 2

Pertussis

  • Infants <6 months: 10 mg/kg daily for 5 days 3
  • Infants and children ≥6 months: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg daily (max 250 mg) on days 2-5 3

Special Pediatric Conditions

  • Cat scratch disease (≥45 kg): 500 mg on day 1, then 250 mg for 4 additional days 3
  • Cat scratch disease (<45 kg): 10 mg/kg on day 1, then 5 mg/kg for 4 more days 3
  • Chlamydial conjunctivitis (neonates): 20 mg/kg daily for 3 days 3

Administration and Drug Interactions

  • Can be taken with or without food 1
  • Avoid concurrent aluminum or magnesium-containing antacids as they reduce absorption 3
  • If taken with a large meal, absorption may be reduced by up to 50% 7

Cardiac Safety Monitoring

Before initiating azithromycin, obtain an ECG in patients with cardiac risk factors to assess QTc interval 5, 2. This is particularly critical for:

  • Long-term therapy regimens 3
  • Patients taking other QT-prolonging medications 3
  • Elderly patients with cardiac disease 5

Contraindications based on QTc:

  • Men: QTc >450 ms 5, 2
  • Women: QTc >470 ms 5, 2

Renal and Hepatic Dosing

  • Renal impairment (GFR 10-80 mL/min): No dosage adjustment needed 1
  • Severe renal impairment (GFR <10 mL/min): Use with caution; AUC increases 35% 1
  • Hepatic impairment: No established dosing recommendations; pharmacokinetics not studied 1

Common Adverse Effects

  • Gastrointestinal: Diarrhea, abdominal pain, nausea, vomiting (generally mild to moderate) 3, 5
  • Incidence: Approximately 3% experience nausea/vomiting 5
  • Better tolerated than erythromycin with fewer GI side effects 6, 7

Critical Resistance and Stewardship Considerations

Azithromycin's 68-hour half-life creates a prolonged "window" of subinhibitory concentrations (14-20 days for complete elimination), which may promote selection of resistant organisms 4. This is particularly concerning for:

  • Streptococcus pneumoniae (carriage rates of resistant strains increased to 55% at 2-3 weeks post-treatment in one study) 4
  • Group A streptococcus (geographically variable resistance) 2

Never use azithromycin as monotherapy for gonorrhea due to widespread resistance; always combine with ceftriaxone if gonococcal infection suspected 3.

Monitoring for Long-Term Therapy

  • Baseline liver function tests before initiating chronic therapy 3
  • Baseline ECG for QTc assessment 3
  • Minimum 6-month duration required to demonstrate benefit in bronchiectasis 3
  • Assess clinical response at days 5-7 for acute infections 5

Pregnancy and Pediatric Safety

  • FDA Pregnancy Category B 3
  • Preferred over erythromycin in infants <1 month due to lower risk of infantile hypertrophic pyloric stenosis 3
  • Safety of re-dosing after vomiting: Not established for the 30 mg/kg single-dose regimen, though 8 patients in clinical trials were successfully re-dosed at the same total dose after vomiting within 30 minutes 1

References

Guideline

Azithromycin Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Azithromycin Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Azithromycin Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.